Latest EMA’s updates on the use of RWE in regulatory decision-making

The third annual report on the integration of real-world evidence (RWE) into regulatory decision-making shows a marked increase in the number of RWE studies conducted by the three pathways for generating RWE, the European consortium DARWIN EU, the framework contract (FWC), and in-house EMA studies. The PRAC Committee gave rise to the higher number of requests in the monitored period

EU Life Sciences Strategy, comments to the call for evidence

The call for evidence closed on 17 April, and the proposal of the draft EU Life Sciences Strategy is expected by Q2 2025. It should encompass all the different industrial sectors in which life sciences play a central role for R&D and competitiveness, including pharmaceuticals, biotech and medtech